Modeling apoptosis resistance in CHO cells with CRISPR-mediated knockouts of Bak1, Bax, and Bok.


Journal

Biotechnology and bioengineering
ISSN: 1097-0290
Titre abrégé: Biotechnol Bioeng
Pays: United States
ID NLM: 7502021

Informations de publication

Date de publication:
06 2022
Historique:
revised: 24 01 2022
received: 10 09 2021
accepted: 04 02 2022
pubmed: 19 2 2022
medline: 18 5 2022
entrez: 18 2 2022
Statut: ppublish

Résumé

Chinese hamster ovary (CHO) cells are the primary platform for the production of biopharmaceuticals. To increase yields, many CHO cell lines have been genetically engineered to resist cell death. However, the kinetics that governs cell fate in bioreactors are confounded by many variables associated with batch processes. Here, we used CRISPR-Cas9 to create combinatorial knockouts of the three known BCL-2 family effector proteins: Bak1, Bax, and Bok. To assess the response to apoptotic stimuli, cell lines were cultured in the presence of four cytotoxic compounds with different mechanisms of action. A population-based model was developed to describe the behavior of the resulting viable cell dynamics as a function of genotype and treatment. Our results validated the synergistic antiapoptotic nature of Bak1 and Bax, while the deletion of Bok had no significant impact. Importantly, the uniform application of apoptotic stresses permitted direct observation and quantification of a delay in the onset of cell death through Bayesian inference of meaningful model parameters. In addition to the classical death rate, a delay function was found to be essential in the accurate modeling of the cell death response. These findings represent an important bridge between cell line engineering strategies and biological modeling in a bioprocess context.

Identifiants

pubmed: 35180317
doi: 10.1002/bit.28062
pmc: PMC9310834
doi:

Substances chimiques

Proto-Oncogene Proteins c-bcl-2 0
bcl-2-Associated X Protein 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1380-1391

Informations de copyright

© 2022 The Authors. Biotechnology and Bioengineering published by Wiley Periodicals LLC.

Références

Arch Toxicol. 2020 Feb;94(2):371-388
pubmed: 32034435
Curr Opin Syst Biol. 2017 Dec;6:1-6
pubmed: 29104947
Cell Death Differ. 2019 Dec;26(12):2682-2694
pubmed: 30976095
Biotechnol J. 2015 Sep;10(9):1446-56
pubmed: 25864574
Science. 2007 Nov 9;318(5852):944-9
pubmed: 17991856
Biotechnol Prog. 2013 May-Jun;29(3):727-37
pubmed: 23596153
Cell Death Dis. 2019 Feb 15;10(3):155
pubmed: 30770792
J Cell Biol. 2017 Oct 2;216(10):3355-3368
pubmed: 28768686
Biotechnol J. 2018 Mar;13(3):e1700229
pubmed: 29027766
J Cell Sci. 2016 Aug 1;129(15):3054
pubmed: 27505430
FEBS Lett. 2000 Sep 1;480(2-3):311-3
pubmed: 11034351
Biotechnol J. 2015 Jul;10(7):979-94
pubmed: 26058577
Cell Death Differ. 2018 Jan;25(1):65-80
pubmed: 29149100
Biochim Biophys Acta. 2016 Aug;1863(8):2115-23
pubmed: 27155082
Proc Natl Acad Sci U S A. 1997 Nov 11;94(23):12401-6
pubmed: 9356461
Biotechnol Prog. 2012 Mar-Apr;28(2):349-57
pubmed: 22492702
Nature. 2000 Oct 12;407(6805):770-6
pubmed: 11048727
Biotechnol Bioeng. 2012 May;109(5):1193-204
pubmed: 22125113
Cell Death Differ. 2013 Jun;20(6):785-99
pubmed: 23429263
FEBS J. 2018 Feb;285(3):416-431
pubmed: 28755482
Cold Spring Harb Perspect Biol. 2013 Apr 01;5(4):a008714
pubmed: 23545417
Biotechnol Adv. 2019 May - Jun;37(3):459-475
pubmed: 30797096
Biotechnol Bioeng. 2014 Aug;111(8):1604-16
pubmed: 24827782
Cell. 2016 Apr 7;165(2):421-33
pubmed: 26949185
Cell Death Differ. 2012 Jun;19(6):915-25
pubmed: 22281706
Biotechnol J. 2018 Oct;13(10):e1800070
pubmed: 29762913
Nat Commun. 2020 Jan 2;11(1):68
pubmed: 31896772
Ann N Y Acad Sci. 2010 Jul;1201:50-7
pubmed: 20649539
Lancet Infect Dis. 2020 Apr;20(4):445-454
pubmed: 32027842
Cytotechnology. 2010 Jul;62(3):175-88
pubmed: 20502964
Cell Death Differ. 2018 Jan;25(1):46-55
pubmed: 29053143
Cell Death Differ. 2006 Aug;13(8):1396-402
pubmed: 16710362
Front Genet. 2017 Jun 16;8:84
pubmed: 28670325
Biotechnol Bioeng. 2022 Jun;119(6):1380-1391
pubmed: 35180317
Biotechnol Bioeng. 2020 Apr;117(4):1187-1203
pubmed: 31930480
Trends Biotechnol. 2004 Apr;22(4):174-80
pubmed: 15038922
Biotechnol Bioeng. 2010 Feb 1;105(2):330-40
pubmed: 19777580
Biotechnol Bioeng. 2006 Jun 5;94(2):373-82
pubmed: 16570314
Biotechnol Bioeng. 2019 Jul;116(7):1813-1819
pubmed: 30883679

Auteurs

Michael A MacDonald (MA)

ARC Training Centre for Biopharmaceutical Innovation, Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St. Lucia, Australia.

Craig Barry (C)

ARC Training Centre for Biopharmaceutical Innovation, Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St. Lucia, Australia.

Teddy Groves (T)

The Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Kgs. Lyngby, Denmark.

Verónica S Martínez (VS)

ARC Training Centre for Biopharmaceutical Innovation, Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St. Lucia, Australia.

Peter P Gray (PP)

ARC Training Centre for Biopharmaceutical Innovation, Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St. Lucia, Australia.

Kym Baker (K)

Patheon by Thermo Fisher Scientific, Woolloongabba, Queensland, Australia.

Evan Shave (E)

Patheon by Thermo Fisher Scientific, Woolloongabba, Queensland, Australia.

Stephen Mahler (S)

ARC Training Centre for Biopharmaceutical Innovation, Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St. Lucia, Australia.

Trent Munro (T)

ARC Training Centre for Biopharmaceutical Innovation, Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St. Lucia, Australia.

Esteban Marcellin (E)

ARC Training Centre for Biopharmaceutical Innovation, Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St. Lucia, Australia.
Metabolomics Australia, The University of Queensland, Brisbane, Queensland, Australia.

Lars K Nielsen (LK)

ARC Training Centre for Biopharmaceutical Innovation, Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St. Lucia, Australia.
The Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Kgs. Lyngby, Denmark.

Articles similaires

Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice
Animals Tail Swine Behavior, Animal Animal Husbandry

Classifications MeSH